Tinidine antitumor drugs are a new class of biotargeted antitumor drugs. Currently, the common antitumor drugs of tinidine in China’s market include: gefitinib, imatinib, imatinib mesylate, nilotinib, sunitinib and lapatinib.
Gefitinib, developed by astrazeneca, UK, is the first molecular targeted therapy for non-small cell lung cancer. It works by selectively inhibiting the signaling pathway of the epidermal growth factor receptor tyrosine kinase (egfr-tk).
Imatinib is a new type of 2-aniline pyrimidine tyrosine kinase inhibitor. It can effectively inhibit the activity of bcr-abl tyrosine kinase at the cellular level, which is the product of abnormal expression of Ph chromosome in chronic granulocytic leukemia (CML). Therefore, imatinib can selectively inhibit the proliferation and apoptosis of cells in the positive cell line of ber-abl and patients with chronic granulocytic leukemia.
Sunitinib is a multi-target tyrosine kinase inhibitor, including platelet derived growth factor receptor, vascular endothelial growth factor receptor, and various forms of mutations that activate stem cell factor receptor, inhibiting tumor cell RTKs expression disorder and anti-tumor angiogenesis. Metabolism relies on cytochrome P450 enzymes. It is suitable for patients with gastrointestinal stromal tumors who are resistant to imatinib or who progress after treatment, or for the treatment of renal cell carcinoma.
Post time: Aug-06-2018